Gabapentin Tablet
Product Images NDC 77771-178

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 77771-178). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Radha Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Tablets, Usp 600 mg (500 Tablets label)

Gabapentin Tablets USP 600 mg oral tablet label from Radha Pharmaceuticals, Inc. The label indicates a package size of 500 tablets and includes dosage and storage information, a bar code, and the NDC number 77771-177-05. It is clearly marked Rx only.*

FDA Label Image

Gabapentin Tablets, Usp 600 mg (100 Tablets label)

Gabapentin Tablets USP 600 mg oral tablet label from Radha Pharmaceuticals, Inc. The label indicates the package contains 90 tablets and is for prescription use only. It includes dosing storage instructions and cautions, a barcode, and the NDC number 77771-177-90.*

FDA Label Image

Gabapentin Tablets, Usp 800 mg (500 Tablets label)

Gabapentin Tablets, USP 800 mg oral tablets label from Radha Pharmaceuticals, Inc. The label indicates a package of 500 tablets with NDC 77771-178-05. It includes storage instructions, dispensing guidance, manufacturer and distributor information, a barcode, and a note to provide a Medication Guide when dispensing.*

FDA Label Image

Gabapentin Tablets, Usp 800 mg (100 Tablets label)

Label for Gabapentin Tablets, USP 800 mg oral tablets by Radha Pharmaceuticals, Inc. Contains 90 tablets, Rx only. Includes pharmacist instruction to provide a medication guide, storage and dispensing information, and manufacturer details in text. Barcode and size indication 1.0" x 2.0" NO VARNISH are also visible.*

FDA Label Image

Figure 1 (Image 01)

A line graph showing mean pain score over eight weeks comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks, including baseline, a 4-week dose titration period, and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin's pain score decreases more significantly over time compared to placebo.*

FDA Label Image

Figure 2 (Image 02)

Line graph showing mean pain scores over seven weeks for three groups: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, with pain scores generally decreasing for Gabapentin groups compared to placebo.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares the percentage of responders in two studies for placebo (PBO) and gabapentin (GBP) doses, showing higher response rates in gabapentin groups, with significance markers (p < 0.01, p < 0.001).*

FDA Label Image

Image-04 (Image 04)

A mathematical formula for calculating creatinine clearance (CLCr), which includes age, weight, and serum creatinine, with an adjustment factor for female patients. The formula is displayed clearly as a fraction.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of Gabapentin showing a cyclohexane ring attached to amino and carboxyl functional groups.*

FDA Label Image

Image-09 (Image 09)

A scatter plot showing percentage difference versus daily dose in mg. The chart compares three studies labeled a, b, and c, with daily doses ranging from 600 mg to 1800 mg plotted on the x-axis and percentage difference on the y-axis. Study a is represented by black squares, Study b by gray squares, and Study c by white squares.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.